The goal of this clinical trial is to learn if a non-invasive electrical therapy (called TEAS) applied to specific points on the skin can help patients with severe liver disease better tolerate emergency stomach scope for serious bleeding. It will also test whether TEAS improves procedural efficiency, hemostasis outcomes, and patient tolerance. The main questions the study aims to answer are: 1. Does TEAS shorten procedure time for diagnostic and therapeutic endoscopy? 2. Does TEAS improve immediate hemostasis success and reduce early rebleeding? 3. Does TEAS reduce patient discomfort and improve procedural tolerance during urgent endoscopy? Researchers will compare three approaches: 1. Active TEAS: Electrical stimulation at specific points on hands/legs before and during the scope.. 2. Sham TEAS: Pads placed on the skin but no electrical stimulation. 3. Control: Standard procedure without any pads or stimulation. Participants with acute upper digestive bleeding due to liver disease who need an emergency scope will: 1. Be randomly assigned to one of the three groups. 2. Receive either Real TEAS, Sham TEAS, or No TEAS just before and during their emergency stomach scope procedure. 3. Have procedural efficiency (time) and hemostasis outcomes recorded. 4. Have discomfort levels assessed using a Visual Analogue Scale (VAS). 5. Have physiological parameters (heart rate, blood pressure, respiratory rate) monitored. 6. Be evaluated for endoscopic success, patient satisfaction, and clinical experience measures. Researchers will watch for any side effects from the TEAS pads or the procedure.
Background and Rationale: Acute esophagogastric variceal bleeding (AEGVB) in cirrhotic patients is a life-threatening emergency requiring urgent endoscopic intervention. Emergency endoscopy, often performed under conscious sedation or minimal anesthesia due to the urgency and patient instability, is associated with significant patient discomfort, poor tolerance, hemodynamic fluctuations (tachycardia, hypertension), nausea/vomiting, and compromised procedural success. This discomfort can lead to suboptimal visualization, incomplete treatment, and increased risk of complications. Effective, low-risk adjunctive methods to improve tolerance and stability during this critical procedure are needed. Transcutaneous Electrical Acupoint Stimulation (TEAS) is a non-invasive modality derived from traditional acupuncture principles, delivering controlled electrical currents to specific acupoints via surface electrodes. Preliminary evidence suggests TEAS may reduce procedural discomfort, promote hemodynamic stability, regulate gastrointestinal function, and potentially enhance hemostasis. However, robust evidence on its efficacy and safety specifically during urgent endoscopy for AEGVB in cirrhotic patients is lacking. This trial aims to rigorously evaluate whether adjunctive TEAS improves procedural tolerance and clinical outcomes in this high-risk population. Study Design and Methodology: This is a prospective, randomized, single-center, three-arm, controlled trial. Cirrhotic patients presenting with EGVB requiring urgent endoscopy within 48 hours will be assessed for eligibility. Eligible and consenting participants will be randomly assigned (1:1:1) using computer-generated random numbers with allocation concealment to one of three groups: Active TEAS Group: Receives real TEAS stimulation applied bilaterally to four predefined acupoints (Hegu \[LI4\], Neiguan \[PC6\], Zusanli \[ST36\], Gongsun \[SP4\]) using a standardized device (dense-disperse wave, 2/100Hz frequency, intensity adjusted to patient tolerance \[typically 5-15mA\]). Stimulation begins 10 minutes before endoscope insertion and continues throughout the endoscopic procedure. Sham TEAS Group: Receives identical electrode placement at the same acupoints using the same device, but no electrical current is delivered (device appears active). This controls for the placebo effect of device application and acupressure. Control Group: Receives standard urgent endoscopy care without any TEAS electrodes or device application. All participants receive standardized pre-endoscopic medical management (fluid resuscitation, vasoactive drugs, antibiotics as indicated) and undergo the urgent endoscopic procedure (diagnostic and therapeutic) performed by experienced endoscopists blinded to group assignment, using institutional protocols. The TEAS/sham operator is not involved in outcome assessment. Primary Focus: The study primarily investigates whether active TEAS, compared to sham or standard care: 1. Enhances procedural efficiency: Measured as total endoscopy time for diagnostic and therapeutic procedures. 2. Improves hemostasis outcomes: Including immediate hemostasis success and 7-day rebleeding rate. 3. Ameliorates procedural tolerance: Assessed via patient-reported discomfort (VAS), endoscopy success rate, and physiological stability. Safety Monitoring: Adverse events related to TEAS (e.g., local skin irritation, pain at electrode sites) and the endoscopic procedure (e.g., aspiration, perforation) are meticulously recorded and managed per protocol. Scientific Justification: The selection of specific acupoints (LI4, PC6, ST36, SP4) is based on traditional Chinese medicine principles and modern physiological understanding: targeting points associated with analgesia (LI4, PC6), gastrointestinal motility regulation and anti-emesis (PC6, ST36), hemodynamic stabilization (PC6), and potential enhancement of hemostatic mechanisms (SP4, ST36). The sham-controlled design is crucial for isolating the specific effects of electrical neuromodulation from non-specific placebo effects. This trial addresses a significant gap in optimizing the high-stakes scenario of urgent endoscopy for AEGVB by evaluating a readily deployable, non-pharmacological adjunctive strategy.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
DOUBLE
Enrollment
180
Participants receive real Transcutaneous Electrical Acupoint Stimulation (TEAS) delivered via surface electrodes bilaterally at four predefined acupoints (Hegu \[LI4\], Neiguan \[PC6\], Zusanli \[ST36\], Gongsun \[SP4\]). Stimulation (dense-disperse wave, 2/100Hz frequency, intensity 5-15mA based on tolerance) begins 30 minutes before urgent endoscopy and continues throughout the procedure. All participants receive standard medical management and urgent endoscopy.
Participants receive placebo TEAS. Electrodes are placed identically to the Active TEAS Group at the same four acupoints (Hegu \[LI4\], Neiguan \[PC6\], Zusanli \[ST36\], Gongsun \[SP4\]) using the same device, but no electrical current is delivered. The device appears active to maintain blinding. All participants receive standard medical management and urgent endoscopy.
Participants receive standard urgent endoscopy care only, with no TEAS electrodes or device applied. They receive identical standard medical management and urgent endoscopy as the other groups.
The Fifth Medical Center of PLA General Hospital
Beijing, Beijing Municipality, China
Procedural Efficiency
Total endoscopy time (minutes), recorded from scope insertion to withdrawal, analyzed separately for diagnostic-only procedures and therapeutic interventions.
Time frame: Immediately after the endoscopy procedure
Hemostasis Outcomes
1. Immediate hemostasis success: Defined as cessation of active bleeding observed at procedure completion. 2. 7-day rebleeding rate: Defined as clinically significant bleeding from the same source within 7 days post-procedure.
Time frame: Within 7 days post-procedure
Discomfort Level
A self-made questionnaire comprising five visual analogue scales (VASs) evaluated discomfort across nausea and vomiting, throat discomfort, bucking, abdominal distension/pain, and agitation. Each VAS was a 10 cm horizontal line segment scored from 0 (no discomfort) to 10 (highest discomfort intensity), where patients marked their perceived level for each symptom. All participants completed the five VASs at 30 minutes post-procedure, and the mean score was calculated.
Time frame: At 30 minutes post-procedure
Blood pressure
Blood pressure is measured in millimeters of mercury (mmHg). Systolic blood pressure and diastolic blood pressure were continuously monitored also using a multiparameter patient monitor (Type Prince-100B, Heal Force Bio-meditech Holdings Limited, China). Measurements were recorded at three phases: pre-endoscopy (baseline), during active endoscopy, and 30 minutes post-procedure to evaluate hemodynamic responses to the intervention.
Time frame: At pre-endoscopy (baseline), during active endoscopy, and 30 minutes post-procedure
Heart rate
Heart rate (unit of measure: beat per minute) was continuously monitored using a multiparameter patient monitor (Type Prince-100B, Heal Force Bio-meditech Holdings Limited, China). Measurements were recorded at three phases: pre-endoscopy (baseline), during active endoscopy, and 30 minutes post-procedure to evaluate hemodynamic responses to the intervention.
Time frame: At pre-endoscopy (baseline), during active endoscopy, and 30 minutes post-procedure
Procedural Tolerance
A composite endpoint of endoscopy success, requiring both technical adequacy (complete visualization score 4/4) and patient satisfaction (Likert score ≤ 2).
Time frame: Immediately after the endoscopy procedure
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.